Granulocyte-macrophage Colony-stimulating Factor, Interferon Alpha and Interleukin-2 as Adjuvant Treatment for High-risk Renal Cell Carcinoma

NCT01176552 Phase 2 COMPLETED

This prospective study assesses toxicity and potential efficacy of granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon (IFN) alpha and interleukin-2 (IL-2) postoperatively in patients with high-risk renal cell carcinoma (RCC).

Details

Lead sponsor	Kidney Cancer Research Bureau
Phase	Phase 2
Status	COMPLETED
Enrolment	35
Start date	2004-05
Completion	2010-05

Conditions

• Renal Cell Carcinoma

Interventions

• GM-CSF, IFN alpha and IL-2

Primary outcomes

• Disease-free survival (DFS) — 3.5 years

Countries

Russia